Following on from similar work completed with the West Yorkshire Association of Acute Trusts (WYAAT), Akeso were invited to complete and options appraisal and business justification case regarding the future of two Bristol based NHS Trusts and their combined Pharmacy and Technical Services.
Following Lord Carter of Coles’ 2020 Transforming Aseptic Care in England report, several trusts have been conducting options appraisals with the aim of investing to modernise facilities, cope with expected demand growth and reduce reliance on non-NHS medication suppliers.
Following work completed with WYAAT, Akeso were tasked with conducting an options appraisal to review the future of a combined pharmacy technical services for University Hospital Bristol and Weston and the North Bristol Trust.
We completed an options appraisal starting with site visits, interviews with clinical leads and data gathering sessions to understand the current operational activity. Following workshop sessions, we defined project specific critical success factors and explored what the options for appraisal could look like.
Through extrapolation of baseline data, we were able to build modelled scenarios for each option over a 25-year period starting with the do nothing and do minimum options which reflected shut down of operations and continuation of as-is operations, respectively.
Modelled scenarios reviewed potential refurbishment of a new on-site facility on the UHBW Trust site and leasing of a new facility off site. Cost elements were considered from the baseline data and assumptions made following discussions with clinical lead, estate and facilities colleagues, financial colleagues and wider NHS experts. The preferred option was selected based on CSF and VfM scoring.
Akeso successfully demonstrated that the preferred option will be for a new off site hub facility.
Akeso completed a short form business case in full in line with HMT Five Case Methodology for the preferred option which require initial capital investment of c. £24.5m but result in lifecycle savings of approximately £200m (relative to the do minimum).